WARNING LETTER
DFI Co., Ltd.
MARCS-CMS 705464 —
May 06, 2025
Delivery Method:
VIA Electronic Mail
Product:
Medical Devices
Recipient:
Recipient Name
Jeong-Hee Jang
Recipient Title
President and CEO
DFI Co., Ltd.
388-25 Gomo-Ro Jillye-Myeon
Gimhae-si
Gyeongsangnam-do
50875
South Korea
(b)(6)@dficare.com
Issuing Office:
Center for Devices and Radiological Health
United States
WARNING LETTER
May 6, 2025
Dear Mr. Jang,
During an inspection of your firm located in Gimhae, Gyeongsangnam, Korea on January 6, 2025 through January 9, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures CYBOW 11 Reagent Strips for Urinalysis (CYBOW 11). Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.
Quality System Regulation Violations
This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21,
Code of Federal Regulations
(CFR), Part 820. We received a response from Ms. Yong-Ae Park, Chief Research and Development Manager, dated January 23, 2025, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:
1. Failure to establish and maintain adequate procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a). Specifically, your firm’s 2022 to 2024 complaint logs showed that not all complaints were entered into your firm’s complaint handling system for evaluation, investigation, and MDR evaluation. For example, the following complaints involving the possible failure of the device to meet any of its specifications were not entered:
a. Analyzer complaint #60 in 2022 was received on January 17, 2022, due to “Leukocyte shows false negative, Nitrite shows false positive;”
b. Strip complaint #16 in 2022 was received on August 4, 2022, due to “All parameters are showing positive results;”
c. Strip complaint #16 in 2023 was received on May 19, 2023, due to “False negative for Blood;”
d. Analyzer complaint #6 in 2024 was received on January 15, 2024, due to “After dipping in water, Bld/Nit/Leu appear false positive;” and
e. Strip complaint #25 in 2024 was received on December 3, 2024, due to “High concentration shows delayed or no color development.”
Your firm’s representative, Ms. Yong-Ae Park, stated to the investigator that many of the complaints were not entered into the complaint handling system because they were handled informally by the sales department.
We reviewed your firm’s response and conclude that it is not adequate. Your firm identified the root cause of the problem as, “the reason for not issuing the report is not clearly indicated, so we have updated it by adding it to the procedures.” Your firm’s response did not include a description or evidence that the specific complaints identified in the FDA 483 have been investigated. Your firm provided DFI-OP-801(V10) titled Customer complaints. While your firm noted that you updated your procedure to include situations where customer complaint reports would not be issued, the updated procedure document is inadequate. The procedure does not ensure that all complaints are processed in a uniform and timely manner, as required by 21 CFR 820.198(a)(1); it does not include timeframes for evaluating and reviewing complaints. Specifically, it does not ensure that complaints which require a 5-day or 30-day report in accordance with 21 CFR Part 803 are evaluated in a timely manner. Additionally, the updated customer complaint document allows for specific complaints involving the possible failure of the device to meet its specifications to not be reviewed, evaluated, and investigated (e.g., when abnormal color development is caused by the interfering substances mentioned in the insert). This procedure, allowing for such complaints to not be reviewed, evaluated, or investigated, does not meet the requirement of 21 CFR 820.198(c).
Once an adequate complaint handling procedure is established your firm should provide evidence of training on the new procedure for all personnel who may receive complaints, including the sales department. Additionally, your firm should conduct a retrospective review to determine if corrections are needed in response to other complaints involving the possible failure of the device, labeling, or packaging to meet any of their specifications which were not appropriately investigated. A summary of the findings and a remediation plan, if necessary, should be provided.
2. Failure to establish and maintain adequate procedures to control product that does not conform to specified requirements, as required by 21 CFR 820.90. For example:
a. The investigator noted that during manufacture of the protein reagent (used in the manufacturing of the CYBOW 11), that the reagent failed the pH test three times but only the third failure
(b)(4)
was documented in the production record. Your firm’s representative, Ms. Yong-Ae Park, stated to the investigator that the technician did not believe in the failed results, and therefore, he repeated the tests.
b. Page 6, Section 5 (subtitled 1st QC check) of the manufacturing process technical file provided during the investigation shows that your firm allows for a recheck of failed QCs during this stage of the workflow (1st QC check).
c. Page 15, Section 12 (subtitled 3rd QC check) of the manufacturing process technical file provided during the investigation shows that your firm allows for a recheck of failed QCs during this stage of the workflow (3rd QC check).
We reviewed your firm’s response and conclude that it is not adequate. With regards to the retesting failed pH values, your firm indicated that you revised your documentation (DFI-WIC-014(V2) Reagent manufacture_20250113) to include instructions that
(b)(4)
. Additionally, the revision instructs
(b)(4)
. While the revision to the reagent manufacture document addresses the identification, documentation, and evaluation of the nonconformance, it does not address segregation and disposition of the nonconforming product, nor does it specify whether the evaluation and any investigation shall be documented, as required by 21 CFR 820.90 (a). Additionally, your firm has not provided evidence to support that you have procedures that define the responsibility for review and the authority for the disposition of nonconforming product. The procedures must include instruction that disposition of nonconforming product shall be documented and shall include the justification for use of nonconforming product and the signature of the individual(s) authorizing the use, as required by 21 CFR 820.90 (b)(1).
Your firm stated in your response, for the 1st QC check (described in the cover letter as semi-product), that, “
If the result of the actual QC Inspection (Semi-Product(I) fails, we do not reconfirm, but it is incorrectly recorded in the Manufacturing Process and corrected
.” Your firm provided the revised document titled, “2-TCF31D0-10_Manufacture process
(b)(4)
.” However, item 2, section 5.5 in this document subtitled, “Processing of Inspection LOT” states, “
Rejected Lot:
If passed after a retest
, it is put into the next process and discarded when rejected
,” (emphasis added). Therefore, this response is inadequate because the revised document still includes language that allows users to retest without requiring that the nonconformance be evaluated and a determination of the need for an investigation be made in accordance with 21 CFR 820.90(a).
As pertains to the 3rd QC check, your firm indicated in your response that this stage relates to the finished product and looks at two things: the test paper, and the packaging. Your firm indicates that if there is a problem with the test paper, you would
(b)(4)
. Your firm provided the revised manufacturing process document and your nonconformity procedure to support this response. The revised manufacturing process document now states “
(b)(4)
” and the nonconformity product management document provided in your firm’s response includes a reference to “
(b)(4)
”. However, the documentation provided by your firm does not require that
(b)(4)
, including a determination of any adverse effect from the
(b)(4)
the product, shall be documented in the device history record, as required by 21 CFR 820.90(b)(2). Further, your firm did not include reference to systemic corrective actions to ensure that adequate procedures are in place to control all product that does not conform to specified requirements as required by 21 CFR 820.90.
Once an adequate nonconforming product procedure is established, your firm should provide evidence of training on the new procedures. Additionally, your firm should conduct a retrospective review to determine if other nonconforming product was appropriately handled. A summary of the findings and a remediation plan, if necessary, should be provided.
3. Failure to establish and maintain adequate procedures to control labeling activities, as required by 21 CFR 820.120. Specifically, your firm’s representative, Ms. Yong-Ae Park, stated to the investigator that your firm does not have a written procedure to control labeling activities, and that your firm’s device history records (DHR) do not include or refer to the location of the primary identification labeling nor the unique device identifiers (UDI) used for each production unit/lot/batch for the CYBOW 11. The DHRs reviewed during the investigation did not include or refer to the location of the label and labeling used (primary label/UDI label) for each production unit/lot/batch. Ms. Yong-Ae Park informed the investigator that she did not know that the primary labeling (including UDIs) needs to be included as part of the DHRs.
We reviewed your firm’s response and conclude that it is not adequate. Your firm provided documentation indicating that you added information relating to labeling to your inspection standard forms for raw and finished products related to the CYBOW 11, as well as an import inspection certificate for the label and a QC inspection report form with a location for the label. Your firm also provided documentation from a specific lot showing the implemented changes as well as training records demonstrating that staff have been trained on the inspection of finished products. However, while the documents mention label integrity, your firm has not provided evidence to show that you have implemented activities to ensure that labels shall be printed and applied so as to remain legible and affixed during the customary conditions of processing, storage, handling, distribution, and where appropriate use as required by 21 CFR 820.120(a).
Additionally, your firm’s test inspection standard, which applies to the finished product, does not include information to show, as required by 21 CFR 820.120(b), that the labeling shall not be released for storage or use until a designated individual(s) has examined the labeling for accuracy including, where applicable, the correct UDI or universal product code (UPC), expiration date, control number, storage instructions, handling instructions, and any additional processing instructions. It also does not require that the release, including the date and signature of the individual(s) performing the examination, be documented in the DHR. Also, the documentation provided does not include information on labeling storage as required by 21 CFR 820.120(c), to support that labeling shall be stored in a manner that provides proper identification and is designed to prevent mix-ups.
Further, the response is inadequate because your firm did not include reference to systemic corrective actions to ensure that you have procedures to control labeling activities for products other than the CYBOW 11, as required by 21 CFR 820.120. Once adequate labeling control procedures are established, your firm should provide evidence of training on the new procedures.
4. Failure to establish and maintain procedures to ensure that DHRs for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the DMR and the requirements of 21 CFR 820.184. For example, per your firm’s mixing procedure forms listed below, technicians are not required to document the time and speed for the mixing procedures for the reagents of the CYBOW 11 reagent strips for urinalysis:
Urobilinogen Operation Procedure
Glucose Operation Procedure
Bilirubin Operation Procedure
Ketones Operation Procedure
SG Operation Procedure
Blood Operation Procedure
PH Operation Procedure
Protein Operation Procedure
Nitrite Operation Procedure
Leukocytes Operation Procedure
ASA Operation Procedure
Specifically, two DHR logs reviewed during the inspection (DHR for Lot 240104 and lot 240619) confirm that technicians do not document the time and speed for the mixing procedures to show that these activities were performed.
We reviewed your firm’s response and conclude that it is not adequate. Your firm provided operation procedure documents for each of the reagents of the CYBOW 11. While your firm updated your reagent operating procedures with temperature, speed, and time ranges for each step of the process that requires mixing, the updated operating procedure documents are inadequate because you do not demonstrate that the device is manufactured in accordance with the DMR as required by 21 CFR 820.184. Specifically, the updated operating procedure documents do not instruct technicians to document in the production record, the exact temperatures, speed, and times at which you mixed the reagents. The DHR is intended to provide objective evidence that the requirements of the DMR were met and information to facilitate failure investigations and corrective or preventive actions. Lack of detail in the DHR will prevent a manufacturer from adequately investigating nonconformances.
Additionally, the response is inadequate because your firm did not include reference to systemic corrective actions to ensure that DHRs for products other than the CYBOW 11 are maintained to demonstrate that they are manufactured in accordance with the DMR and the requirements of 21 CFR 820.184. Once adequate reagent operating procedures are established, your firm should provide evidence of training on the new procedure. Additionally, your firm should conduct a review to determine if all DHRs are complete. A summary of the findings and a remediation plan, if necessary, should be provided.
5. Failure to adequately identify by suitable means the acceptance status of product, to indicate the conformance or nonconformance of product with acceptance criteria, as required by 21 CFR 820.86. Specifically, the original production identification (Pass/Fail) label used in the manufacture of the CYBOW 11 was not maintained. For example, while the manufacturing process document reviewed during the inspection states that all production processes are documented and controlled, the investigator noted that during manufacturing, the label used to track the reagent to show it was approved for use by QC is discarded after the product is moved to the next process. Your firm’s representative, Ms. Yong-Ae Park, stated to the investigator that the label is discarded once the reagent is moved to the next process.
We reviewed your firm’s response and conclude that it is not adequate. In your response, your firm addressed the observation by providing multiple updated documents including: (i) the standard operating procedures for the
(b)(4)
processes, with added language to ensure that users confirm the presence of the QC approval seal, (ii)
(b)(4)
working forms, with a check box added to confirm the Lot number and QC acceptance for the dipping work product, and (iii) training forms to show that users were trained on the revised steps. However, the response is inadequate because your firm did not conduct a review to ensure that products other than the CYBOW 11 are also subjected to adequate acceptance status activities. A summary of the findings and a remediation plan, if necessary, should be provided.
Medical Device Reporting (MDR) Violations
Our inspection also revealed that you have failed to develop, maintain, and implement written Medical Device Reporting (MDR) procedures, as required by 21 CFR 803.17. For example: during the inspection, your firm presented the document titled “FDA Medical Decivice [sic] Reporting”, DFI‐OP‐816, Revision No. 1, dated 2023.05.01 as its written MDR procedure. Upon review, we conclude that the procedure does not establish internal systems that provide for timely and effective identification, communication, and evaluation of events that may be subject to MDR requirements, as required by 21 CFR 803.17(a)(1). For example, the procedure omits the definition of the term “malfunction” from 21 CFR 803.3(k), and fails to specify what kind of information “reasonably suggests” that an MDR reportable event has occurred per 21 CFR 803.20(c)(1). The exclusion of the definitions for these terms from the procedure may lead your firm to make an incorrect reportability decision when evaluating a complaint that may meet the criteria for reporting under 21 CFR 803.50(a).
We reviewed your firm’s response and conclude that it is not adequate. The response includes a copy of your firm’s revised MDR procedures titled “FDA Medical Decivice [sic] Reporting”, DFI‐OP‐816, Revision No. 2, dated 2025.01.15. Upon review of the revision, we note that it still fails to specify what kind of information “reasonably suggests” that an MDR reportable event has occurred per 803.20(c)(1). Additionally, we encourage your firm to conduct a retrospective review to determine if corrections are needed for other complaints involving the possible failure of the device, labeling, or packaging to meet any of their specifications which were not appropriately investigated for reportability.
We note that a device is deemed to be misbranded under section 502(t)(2) of the Act, 21 U.S.C. § 352(t)(2), if there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting the device, including adverse event reports required under 21 CFR Part 803.
Other federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.
Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and/or corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and/or corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and/or corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and/or corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.
Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov. Refer to CMS case # 705464 when replying. If you have any questions about the contents of this letter, please contact: Christine Kilonzo at Christine.kilonzo@fda.hhs.gov.
Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the
Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.
Sincerely yours,
/S/
Courtney H. Lias, Ph.D.
Director
OHT 7: Office of In Vitro Diagnostic Devices
Office of Product Evaluation and Quality
Center for Devices and Radiological Health
CC:
Ms. Young Ae Park
Chief Research and Development Manager DFI Co., Ltd.
(b)(6)
@dficare.com
Priscilla Chung
LK Consulting Group USA, Inc.
US Agent
juhee.c@lkconsultinggroup.com
Content current as of:
06/03/2025
Regulated Product(s)
Medical Devices